Summary
This clinical trial is testing new immunotherapy treatments for people with advanced liver cancer, also called hepatocellular carcinoma (HCC).
The main aims of the study are to find out:
- How safe the study treatments are
- What side effects may occur
- How well the treatments can control or shrink the cancer
Who can take part?
You may be able to join this study if you:
- Are aged 18 years or older
- Have advanced or inoperable liver cancer (HCC) that cannot be removed with surgery
- Have not had systemic treatment for advanced HCC before
The study team and your doctor can carefully check if the trial is suitable for you.
Study details
This is a Phase 1/2 clinical trial, Phase 1 looks closely at safety and side effects. Phase 2 explores how well the treatment works compared to other treatments.
Within each phase, there are multiple treatment groups. Eligible participants will be randomly allocated (by chance) to one of the treatment groups. These may include receiving:
- pumitamig immunotherapy with ipilimumab immunotherapy, or
- atezolizumab immunotherapy with bevacizumab targeted therapy, or
- pumitamig immunotherapy on its own